Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Yasuyoshi Arikawa

Haruyuki Nishida

Masahiro Ito

Hironobu Maezaki

Ikuo Fujimori

Yasuhiro Imaeda

Akinori Toita

Hironori Kokubo

Koji Ono

Qing Dong

Toshio Tanaka

Zhe Nie

Shigenori Ohkawa

Christopher Ronald Smith

Benjamin Jones

Hidekazu Tokuhara

Hiroshi Banno

Betty Lam

Takaharu Hirayama

Jinichi Yonemori

Masaki Setoh

Masahiro Okura

Masashi Takahashi

Victoria Feher

Kouki Kato

Hideyuki Sugiyama

Takuto Kojima

Tomohiro Okawa

Minoru Sasaki

Keiko Kakegawa

Yasutomi Asano

Ayumu Sato

Tohru Miyazaki

Yasuhiro Hirata

Nobuki Sakauchi

Fumiaki Kikuchi

Nobuo Cho

Misaki Homma

Ryo Mizojiri

Moriteru Asano

Douglas Robert Cary

Jun Fujimoto

Nao Morishita

Osamu Kubo

Keizo Hirase

Takeshi Yamamoto

Masato Yoshikawa

Masaki Seto

Makoto Kamata

Takahiro Sugimoto

Shinichi Imamura

Toshihiro Imaeda

Yoshiteru Ito

Yuya Oguro

Masahiro Kajino

Zenichi Ikeda

Taku Kamei

Shinobu Sasaki

Hiroshi Imoto

Noriyuki Nii

Tomohiro Ohashi

Youichi Kawakita

Goushi Nishida

Takashi Miki

Takeshi Yasui

Shiinobu Sasaki

Hirotaka Kamitani

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Heterocyclic compound

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

HDAC6 inhibitory heterocyclic compound

The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Fused heteroaromatic pyrrolidinones as SYK inhibitors

Fused heteroaromatic pyrrolidinones

The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R, Rand Rare each a hydrogen atom, a halogen atom, a Calkyl group optionally substituted by halogen or a Calkoxy group optionally substituted by halogen, Rand Rare each a hydrogen atom, a halogen atom or a Calkyl group optionally substituted by halogen, Ris a hydrogen atom, a halogen atom, a Calkyl group optionally substituted by halogen or a Calkoxy group optionally substituted by halogen, and Ris a hydrogen atom or a Calkyl group optionally substituted by halogen or a salt thereof, or a pharmaceutical composition containing the same.

Pyrrole compounds

The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity, which is represented by the formula (I) wherein Ris an optionally substituted cyclic group, Ris a substituent, Ris an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, Rand Rare each a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, Rand Rare each a hydrogen atom or an alkyl group, and n is an integer of 0-3, or a salt thereof.

Provided is a compound having a superior acid secretion suppressive action, which shows an antiulcer activity and the like. A compound represented by the formula (I) or a salt thereof: 

5-Membered heterocyclic compound

Compounds represented by the formula: wherein Rand Rare hydrogen atom, a hydrocarbon group or a heterocyclic group, or Rand Rmay form, together with the adjacent carbon atom, a 3- to 8-membered homocyclic or heterocyclic ring, W indicates a group represented by the formula: wherein Rindicates (1) an aliphatic hydrocarbon group, which may be substituted with an aromatic group, or (2) an acyl group containing an aromatic group, Ris hydrogen atom, a Calkyl, or an acyl group, Rindicates a Caryl group, or salts thereof. The compounds have an excellent action to inhibit neurodegeneration as well as an excellent brain penetrability and are low in the toxicity, thereby being useful as drugs for nerve degenerative diseases.

Benzofuran derivatives, their production and use

Growing community of inventors

Osaka, Japan

Yasuyoshi Arikawa